In its preliminary results, Penumbra expects revenues in the range of $162.5 million to $167.9 million, marking growth of between 12% and 16% when compared to 2019, according to a news release.
Within those figures, Alameda Calif.-based Penumbra included the expected impact of between $5 million and $10 million related to its Dec. 15, 2020, voluntary recall of the Penumbra JET7 reperfusion catheter with Xtra Flex technology. In total, Penumbra expects full-year 2020 revenue to range between $556 million and $561.4 million, totaling between 2% and 3% growth compared to 2019.
The company expects U.S. revenue to represent 69% of its total revenue, with major growth in its vascular product sales marking a 45%-46% uptick from the fourth quarter of 2019. However, neuro product sales are expected to show a decrease of between 5% and 12% compared to the previous year.